Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes

New findings raise the possibility of promising therapeutic strategies for the management of hypoglycemia in type 1 diabetes patients. 

Study: Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes. Image Credit: Anatoliy Cherkas/Shutterstock.com
Study: Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes. Image Credit: Anatoliy Cherkas/Shutterstock.com

In a recent study published in Nature Metabolism, a team of European researchers used polygenic mouse models of human type 1 diabetes to determine the underlying mechanisms of impaired hypoglycemia-induced glucagon secretion.

Background

Type 1 diabetes is an autoimmune disorder in which the body's immune cells attack the β-cells that produce insulin. Insulin regulates blood sugar levels by allowing cells to absorb glucose from the bloodstream. However, type 1 diabetes also involves the dysregulation of the hormone glucagon, which is secreted in the pancreas in response to hypoglycemia and stimulates the liver to release stored glucose into the bloodstream.

The disruption of the glucagon response in individuals with type 1 diabetes leads to dangerously low levels of blood sugar, contributing to close to 10% of the mortality among type 1 diabetes patients. In mouse models of type 1 diabetes, the secretion of glucagon for the counter-regulation of blood sugar levels is restored when treated with somatostatin receptor antagonists. However, the underlying mechanisms of this restored glucagon secretion and whether the same mechanism is effective in humans remains unclear.

About the study

The present study used a widely recognized type 1 diabetes mouse model, the non-obese diabetic or NOD mice, to understand the impaired hypoglycemia-induced secretion of glucagon in type 1 diabetes. The researchers compared the biological mechanisms associated with glucagon secretion in NOD mice with those in non-diabetic mice.

The mice's blood glucose levels were monitored regularly, and they were studied at different ages and compared in various experimental settings. Additionally, other genetically modified mouse models were used to investigate specific cellular activities.

The study also used human islet cells obtained from donors with and without type 1 diabetes, which were cultured for two days before the hormone secretion patterns were studied. The islet cells from the pancreas of the NOD and non-diabetic mice were also isolated and cultured for further analysis.

The researchers performed live-cell calcium imaging on the islet cells, where the cells were immobilized in custom chambers. They also conducted time-lapse imaging using a confocal microscope. The data obtained from this was analyzed to normalize fluorescence signals and calculate the calcium ion oscillation frequency.

The islet cells were also fixed in paraformaldehyde, permeabilized, and then incubated with primary and secondary antibodies to stain for glucagon, insulin, and somatostatin. A glucometer and enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma levels of glucose and glucagon, respectively, before and after insulin injections. In some of the experiments, somatostatin receptor antagonists were also administered.

Furthermore, electrophysiological recordings were conducted for the δ-cells, the endocrine cells in the pancreatic islets that produce somatostatin, which regulates the secretion of insulin and glucagon. Additionally, optogenetic analyses, where light-sensitive proteins are introduced into cells to enable light-based control of cellular activity, were conducted on both β- and δ-cells of the islets.

Molecular methods such as ribonucleic acid (RNA) extraction, copy deoxyribonucleic acid (cDNA) synthesis, and quantitative polymerase chain reaction (qPCR) were conducted to measure gene expression and for glycogen measurements in liver tissue.

Results

The study reported a 97% reduction in the insulin content in the pancreas and a significant decrease in the islet area with no change in the glucagon content. In non-diabetic mice, low blood sugar resulted in strong stimulation of glucagon secretion, but in the NOD mice, the response to hypoglycemia was substantially weaker. However, the capacity to produce and secrete glucagon remained unaffected in the NOD mice, indicating that the problem lay not in the production of the hormone but in the regulation.

The study further found that the NOD mice showed a marked increase in the secretion of somatostatin, which inhibits the release of glucagon, explaining why somatostatin receptor antagonists were effective in mouse models of type 1 diabetes. These findings highlighted the role of excessive somatostatin secretion in the impaired glucagon function in type 1 diabetes.

The study also revealed that the electrical coupling between the β-cells and the somatostatin-producing δ-cells was disrupted in type 1 diabetes. Normally, the activity of the δ-cells would be suppressed by the β-cells in hypoglycemic conditions, preventing the release of somatostatin, which would result in the secretion of glucagon. However, the destruction of β-cells in type 1 diabetes results in the unchecked secretion of somatostatin, inhibiting glucagon release.

Similar disruptions were observed in the human islet cells, with elevated levels of somatostatin and low glucagon secretion even under hypoglycemic conditions. These results suggested that the inhibition of somatostatin could restore the secretion of glucagon, providing a potential therapeutic strategy for the management of hypoglycemia in type 1 diabetes patients.

Conclusions

Overall, the study found that the impaired secretion of glucagon in type 1 diabetes is due to the excessive secretion of somatostatin due to disrupted regulation of δ-cells by the β-cells. Blocking the somatostatin receptors could potentially restore the secretion of glucagon, providing a promising therapeutic strategy for the management of hypoglycemia in type 1 diabetes patients.

Journal reference:
  • Hill, T. G., Gao, R., Benrick, A., Kothegala, L., Rorsman, N., Santos, C., Acreman, S., Briant, L. J., Dou, H., Gandasi, Nikhil R, Guida, C., Haythorne, E., Wallace, M., Knudsen, J. G., Miranda, C., Tolö, J., Clark, A., Davison, L., Størling, J., & Tarasov, A. (2024). Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type1 diabetes. Nature Metabolism. DOI:10.1038/s4225502401139z, https://www.nature.com/articles/s42255-024-01139-z 
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2024, September 27). Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20240927/Why-hypoglycemia-induced-glucagon-secretion-becomes-impaired-in-diabetes.aspx.

  • MLA

    Sidharthan, Chinta. "Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20240927/Why-hypoglycemia-induced-glucagon-secretion-becomes-impaired-in-diabetes.aspx>.

  • Chicago

    Sidharthan, Chinta. "Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes". News-Medical. https://www.news-medical.net/news/20240927/Why-hypoglycemia-induced-glucagon-secretion-becomes-impaired-in-diabetes.aspx. (accessed October 07, 2024).

  • Harvard

    Sidharthan, Chinta. 2024. Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20240927/Why-hypoglycemia-induced-glucagon-secretion-becomes-impaired-in-diabetes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
IBD increases type 1 diabetes risk, revealing a bidirectional link between the two conditions